Drugs /

lifirafenib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.

Clinical Trials

View Clinical Trials for lifirafenib

Lifirafenib has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating lifirafenib, 1 is phase 1/phase 2 (1 open).

KRAS Mutation is the most frequent biomarker inclusion criterion for lifirafenib clinical trials.

Endometrial carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in lifirafenib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lifirafenib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lifirafenib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
beigene-283, bgb-283, begeine-283, bgb 283, braf/egfr inhibitor bgb-283
Drug Categories [2]:
BRAF inhibitors, EGFR inhibitors, Serine/threonine kinase inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
BRAF, EGFR
NCIT ID [1]:
C124995

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.